Vaccines are a matter of national security, a leading global health figure said this week, warning rising anti-vaccine ...

After initially rising toward an all-time high, the S&P 500 flipped between gains and losses before finishing with a minuscule dip of less than 0.1%. The Dow Jones Industrial Average dropped 66 points ...

Today in History for Feb. 26: ...

By Mariam Sunny and Michael Erman Feb 13 (Reuters) - Moderna said it is looking for growth overseas after the U.S. FDA ...

The move is further in line with HHS Secretary Kennedy's anti-vaccine policies ...

The mRNA specialist reiterated its financial estimates for 2026 amid a challenging U.S. regulatory environment where its influenza vaccine just hit a major setback.

Moderna (NASDAQ: MRNA) reported fourth-quarter results Friday morning that beat Wall Street’s muted expectations, delivering revenue of $678 million against estimates of $663 million and a loss of $2.

In a rare and surprising move, the FDA has issued a “Refusal to File” letter for Moderna’s mRNA-1010 influenza vaccine.

Moderna reported falling fourth-quarter sales as Covid-19 vaccine demand continued to drop, but continues to target 10% revenue growth in 2026 following the launch of its next-generation Covid vaccine ...

Reports fourth quarter revenue of $0.7 billion, GAAP net loss of $(0.8) billion and GAAP EPS of $(2.11)Reports ...

Feb 13 (Reuters) - Moderna reported fourth-quarter revenue above Wall Street estimates on Friday, banking on better-than-expected sales of its COVID-19 vaccine in the U.S. The Cambridge, Massachusetts ...